← All trials
NCT05025306
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2020
- Primary completion
- Mar 16, 2020
- Completion date
- Jun 1, 2020
- First posted
- Aug 27, 2021
- Last posted
- Sep 1, 2021
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Lahore Medical and Dental collegeLead sponsor
- Lahore Medical and Dental collegeReponsible party - principal investigator
- Post-Graduate Medical Institute, LahoreOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.